Anti-Titin Antibodies in Myasthenia Gravis
Open Access
- 1 June 2001
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 58 (6) , 885-890
- https://doi.org/10.1001/archneur.58.6.885
Abstract
MYASTHENIA GRAVIS (MG) is an autoimmune disease of the neuromuscular junction characterized by fatigability and weakness of striated muscles.1 It is mediated primarily by autoantibodies directed at the muscle acetylcholine receptor (AChR) in the postsynaptic membrane of the motor end plate.2,3 These autoantibodies are present in the serum of most patients (85%) and can passively transfer the disease to rodents.4 Consequently, they have a major diagnostic and pathogenetic value.Keywords
This publication has 18 references indexed in Scilit:
- Paraneoplastic myasthenia gravis: Detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumorNeurology, 1997
- Titins: Giant Proteins in Charge of Muscle Ultrastructure and ElasticityScience, 1995
- Evaluation of Myosin-Reactive Antibodies from a Panel of Myasthenia Gravis PatientsClinical Immunology and Immunopathology, 1994
- Titin antibodies in myasthenia gravisNeurology, 1993
- Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titinClinical and Experimental Immunology, 1990
- Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin.The Journal of Experimental Medicine, 1986
- Antibody to acetylcholine receptor in myasthenia gravisNeurology, 1976
- Myasthenia Gravis: Passive Transfer from Man to MouseScience, 1975
- Autoimmune Response to Acetylcholine ReceptorScience, 1973
- Immunofluorescence Demonstration of a Muscle Binding, Complement-Fixing Serum Globulin Fraction in Myasthenia Gravis.Experimental Biology and Medicine, 1960